Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors’ conclusions
To enable an accurate assessment to be made of the clinical and cost-effectiveness of fludarabine as first-line treatment for chronic lymphocytic leukaemia there is a need for further evidence to clarify areas of uncertainty.

Project page URL
http://www.hta.ac.uk/erg/supplements/supplement1301.pdf#nameddest=article06

Final publication URL
http://www.hta.ac.uk/1639

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Agents /economics /therapeutic use; Clinical Trials as Topic; Cost-Benefit Analysis; Leukemia, Lymphocytic, Chronic, B-Cell /drug therapy /economics; Quality of Life; Survival Analysis; Technology Assessment, Biomedical; Vidarabine /analogs & derivatives /economics /therapeutic use

Language Published
English

Country of organisation
England

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
32011001401

Date abstract record published
20/10/2011